After three decades climbing the ranks at medical device giants like Boston Scientific and Baxter, a seasoned executive faced a choice that would have given most leaders pause: take the safe route to a public company CEO role, or dive headfirst into the uncertain world of AI in healthcare. The pull toward AI proved irresistible.
AI That Fits the Clinical Workflow: Interview with Anumana CEO Maulik Nanavaty
Related Articles
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening diseaseMay 23, 2022
Anumana expands AI cardiac care platform with support from Boston Scientific
Anumana announced today that it brought its diagnostic ECG-AI technology into perioperative and acute cardiac care with help from Boston Scientific. Read more on massdevice.comApril 24, 2025
Way of Diagnosing PH in Common Heart Test Gets FDA Support
Pulmonary Hypertension News: Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The…May 26, 2022
AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status
Healio: Anumana announced it received FDA breakthrough device designation for its artificial intelligence-guided ECG algorithm for the early identification of cardiac amyloidosis.June 21, 2023